企業概要
Phreesia, Inc. operates as a provider of an integrated SaaS-based software and payment platform designed specifically for the healthcare industry within the United States and Canada. This business model focuses on delivering appointment scheduling systems that facilitate online appointments, reminders, and referral tracking, alongside registration solutions intended to automate administrative processes. The company is positioned within the Healthcare sector, specifically under the Health Information Services industry, which implies a specialized focus on digital infrastructure supporting medical data exchange and patient engagement. With a market capitalization of $661.95M, annual revenue of $463.20M, and an employee base of 2082, the firm demonstrates significant scale relative to many pure-play health tech peers. These valuation and revenue figures suggest that the market recognizes Phreesia as a substantial entity with established operational capabilities, though the capitalization level also reflects the growth-stage dynamics often associated with companies still optimizing their profit margins.
財務健全性
Phreesia reported a revenue of $463.20M for the trailing twelve months, yet recorded a net income of -$5,379,000, while generating an EBITDA of $14.42M. The substantial gap between the reported revenue and the negative net income reveals a cost structure where operating expenses, likely including significant sales and marketing investments typical of SaaS models, are currently outpacing gross profitability to the point of an overall operating loss. However, the company maintains a free cash flow of $33.37M, which provides essential financial flexibility to fund operations and strategic initiatives without relying on external equity financing in the immediate term. The company's margin profile presents a mixed picture: a gross margin of 68.2% indicates efficient product delivery costs, but this is contrasted by an operating margin of -46.7% and a profit margin of -1.2%, signaling that overhead costs are heavily impacting the bottom line. On the balance sheet, the firm holds $439.85M in cash against $12.64M in debt, resulting in a debt-to-equity ratio of 2.60, which suggests a highly leveraged capital structure relative to equity though the absolute debt load is manageable given cash reserves. The current ratio stands at 2.44, indicating a robust position regarding short-term liquidity and the ability to cover current liabilities with current assets. Furthermore, the return on equity is -1.9% and the return on assets is -0.3%, metrics that reveal that management has not yet generated positive returns on the capital invested, a common characteristic for high-growth companies prior to reaching sustained profitability.
バリュエーション評価
The valuation metrics for Phreesia show a trailing P/E ratio of N/A due to the negative net income, whereas the forward P/E is 7.29. This discrepancy between the unavailable trailing P/E and the low forward P/E implies that the market expects a significant improvement in earnings trajectory over the coming twelve months. The price-to-book ratio is 2.06, which indicates that the market values the company at roughly double its net asset book value, suggesting a premium assigned to its intangible software assets and growth potential. Additional valuation measures include a price-to-sales ratio of 1.43 and an EV/EBITDA of 16.27, which provide alternative perspectives on value relative to revenue generation and operating cash flow before interest and taxes. In terms of trading range, the 52-week high is $32.76 and the 52-week low is $10.75, providing a wide band of volatility within which the current trading price resides. The beta value of 0.72 suggests that the stock's price volatility is historically lower than the broader market, meaning it may be less sensitive to general market fluctuations compared to the S&P 500.
Growth & Income
Phreesia is experiencing robust expansion with a revenue growth of 45.7% year-over-year, while earnings growth is listed as N/A due to the current negative net income. Since the earnings growth metric is not available and the net income is negative, it is not possible to calculate a comparative growth rate between revenue and earnings at this time. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm reinvests all available earnings back into the business rather than distributing them to shareholders. This strategy aligns with the company's growth profile, prioritizing capital allocation toward expansion and margin improvement over immediate income generation for investors. The overall growth and income profile for Phreesia is characterized by high revenue acceleration and a complete absence of dividend income, reflecting a classic growth equity approach in the healthcare technology space.